CareDx, Illumina enter next-generation sequencing technologies agreement

Molecular diagnostics company CareDx, which focuses on the development and commercialization of clinically differentiated, noninvasive surveillance solutions for transplant recipients, has entered into a multi-year supply agreement with Illumina that will provide access to next-generation sequencing, microarray equipment, and consumables to the CareDx reference and R&D laboratories.

Jun 25th, 2014

Molecular diagnostics company CareDx (Brisbane, CA), which focuses on the development and commercialization of clinically differentiated, noninvasive surveillance solutions for transplant recipients, has entered into a multi-year supply agreement with Illumina (San Diego, CA) that will provide access to next-generation sequencing, microarray equipment, and consumables to the CareDx reference and R&D laboratories.

Related: Next-gen DNA sequencing enables reliable donor matching service

Illumina develops, manufactures, and markets life science tools and integrated systems for the analysis of genetic variation and function.

Peter Maag, CareDx president and CEO, explains that the company is expanding its pipeline of high-value, transplant diagnostic surveillance solutions from the gene expression-based AlloMap to cell-free DNA-based tests, so Illumina's technology solutions will support CareDx's development and commercialization efforts.

-----

Don't miss Strategies in Biophotonics, a conference and exhibition dedicated to development and commercialization of bio-optics and biophotonics technologies!

Follow us on Twitter, 'like' us on Facebook, and join our group on LinkedIn

Subscribe now to BioOptics World magazine; it's free!

More in Bioscience